stocks logo

DNA

Ginkgo Bioworks Holdings Inc
$
10.130
+0.37(3.791%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.4397
Open
9.970
VWAP
10.15
Vol
1.55M
Mkt Cap
562.54M
Low
9.780
Amount
15.75M
EV/EBITDA(TTM)
--
Total Shares
2.21B
EV
45.62M
EV/OCF(TTM)
--
P/S(TTM)
2.26
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
40.91M
-27.21%
--
--
43.41M
-51.26%
--
--
44.20M
+0.81%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by 3.26% over the past three months. During the same period, the stock price has changed by 38.01%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.26%
In Past 3 Month
Stock Price
Go Up
up Image
+38.01%
In Past 3 Month
5 Analyst Rating
down Image
-11.15% Downside
Wall Street analysts forecast DNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 9.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
3 Sell
Moderate Sell
down Image
-11.15% Downside
Current: 10.130
sliders
Low
6.00
Averages
9.00
High
12.00
TD Cowen
Brendan Smith
Strong Buy
Maintains
$3 → $10
2024-09-20
Reason
BTIG
Mark Massaro
Strong Sell
Maintains
$0.2 → $7
2024-08-23
Reason

Valuation Metrics

The current forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA.N) is -1.68, compared to its 5-year average forward P/E of -16.44. For a more detailed relative valuation and DCF analysis to assess Ginkgo Bioworks Holdings Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.44
Current PE
-1.68
Overvalued PE
14.04
Undervalued PE
-46.93

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-19.09
Current EV/EBITDA
-2.95
Overvalued EV/EBITDA
16.90
Undervalued EV/EBITDA
-55.08

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.64
Current PS
3.38
Overvalued PS
28.58
Undervalued PS
-1.30

Financials

Annual
Quarterly
FY2025Q1
YoY :
+27.34%
48.32M
Total Revenue
FY2025Q1
YoY :
-46.70%
-84.61M
Operating Profit
FY2025Q1
YoY :
-45.18%
-90.96M
Net Income after Tax
FY2025Q1
YoY :
-49.24%
-1.68
EPS - Diluted
FY2025Q1
YoY :
-38.37%
-59.14M
Free Cash Flow
FY2025Q1
YoY :
-0.90%
75.07
Gross Profit Margin - %
FY2025Q1
YoY :
-5.81%
-145.44
FCF Margin - %
FY2025Q1
YoY :
-56.95%
-188.25
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
5.4K
USD
1
3-6
Months
40.4K
USD
6
6-9
Months
34.2K
USD
6
0-12
Months
21.8K
USD
4
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
281.0K
Volume
1
6-9
Months
287.5K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

DNA News & Events

Events Timeline

2025-07-07 (ET)
2025-07-07
12:02:07
Ginkgo Bioworks falls -10.2%
select
2025-06-30 (ET)
2025-06-30
12:00:38
Ginkgo Bioworks rises 17.0%
select
2025-06-11 (ET)
2025-06-11
09:47:22
Ginkgo Bioworks rises 5.4%
select
Sign Up For More Events

News

5.0
07-17PRnewswire
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors
2.0
07-17NASDAQ.COM
Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know
2.0
07-11NASDAQ.COM
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why
Sign Up For More News

FAQ

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) stock price today?

The current price of DNA is 10.13 USD — it has increased 3.79 % in the last trading day.

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s business?

arrow icon

What is the price predicton of DNA Stock?

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s revenue for the last quarter?

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Ginkgo Bioworks Holdings Inc (DNA)'s fundamentals?

arrow icon

How many employees does Ginkgo Bioworks Holdings Inc (DNA). have?

arrow icon

What is Ginkgo Bioworks Holdings Inc (DNA) market cap?